Venture capitalists tempted by German medtech market
This article was originally published in Clinica
"Venture capitalists and other private investment companies are more ready than ever to invest in the German medical technology market," says Thom Rasche, director of the medical consultancy firm MEDEXPERT in Hamburg.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.